Loading
Ran the phase 1 unit that pioneered many targeted therapies, and led the FLAURA trial that made osimertinib first-line.
Jean-Charles Soria is Professor of Medicine at Paris-Saclay and a former Director General of Gustave Roussy. His specialisms are early drug development, EGFR-mutant lung cancer and phase 1 trials. He built the DITEP early-phase unit at Gustave Roussy, which pioneered many targeted therapies, and led FLAURA, the New England Journal of Medicine trial of osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer that made osimertinib the first-line standard. He later served as Director General and as an industry research and development leader before returning to academic medicine. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA) | NEJM | 2018 |
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
ASCEND-4 gave ceritinib its 2017 US first-line approval and showed that a second-generation ALK inhibitor beats chemotherapy in untreated disease. In practice alectinib, brigatinib and lorlatinib, tested against crizotinib rather than chemotherapy, became the usual first-line choices, partly because ceritinib's gut side effects at 750 mg fasted were hard to live with.
Shares First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, ASCEND-4.
Shares First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, ASCEND-4, Non-small-cell lung cancer.
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Non-small-cell lung cancer.
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares FLAURA, Osimertinib, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares FLAURA, Osimertinib, EGFR-mutated non-small-cell lung cancer, EGFR.